Tulane/Xavier Vaccine Peptide Program
Annual rept. 1 July 2012 30 June 2013
TULANE UNIV NEW ORLEANS LA SCHOOL OF MEDICINE
Pagination or Media Count:
The objective of this project is to develop novel formulation strategies for delivery of Flufirvitide-3 and other therapeutic peptides. Therapeutic peptides can be delivered in a non-invasive manner through the nasal mucosa and through the lungs. A wide range of factors, including mode of inhalation and particle size, influence the deposition of aerosols within the respiratory tract. Chemical modification of the Flufirvitide-3 will be evaluated to optimize its functional activity. The use of micro- and nanotechnology will also be explored through the fabrication of particles encapsulating the peptide that are specifically suited for nasal and pulmonary delivery. The micro- and nano-particle carriers to be considered include a dry powder formulation, microemulsions, nonspherical liposomes, ceramic shell vesicles, and nanometer-sized silk particles. Nasal administration of soluble Flufirvitide-3 both pre- and post-exposure to influenza virus has been shown to be effective in preventing infection in an in vivo animal model. However, multiple doses, pre- and post-exposure were required for efficacy. We hypothesize that the proposed techniques will enhance the efficacy of the therapeutic peptide itself, thereby reducing the required dose, number of doses, and thus the cost of treatment, and improve distribution and release within the upper respiratory tract, thus expanding the duration of bioavailability and efficiency of peptide delivery.